Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research AgreementBusiness Wire • 06/07/22
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate HighlightsBusiness Wire • 05/13/22
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022Business Wire • 05/11/22
Kiromic BioPharma Announces Availability of Company's Current Corporate PresentationBusiness Wire • 04/11/22
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate HighlightsBusiness Wire • 04/08/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma, Inc. (KRBP) Investors to Investigation of Possible Securities Law Violations, Encourages Investors with Significant Losses to Contact Firm's AttorneysNewsfile Corp • 03/31/22
Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial ResultsBusiness Wire • 03/11/22
Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company's Board of DirectorsBusiness Wire • 02/03/22
Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QBusiness Wire • 11/24/21
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company's Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid TumorsBusiness Wire • 10/25/21
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid CancersBusiness Wire • 10/11/21
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating HighlightsBusiness Wire • 08/13/21
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid TumorsBusiness Wire • 07/26/21
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid TumorsBusiness Wire • 07/16/21
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid TumorsBusiness Wire • 06/28/21
KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell TherapyBusiness Wire • 06/17/21